We had been investigated{researched} influence hypoprolactiemia and an estimation of the hormonal status at women in preclimax, treatment hormonal preparations for normalization of hormonal parameters is offered
1. Asa SL, Ezzat S. 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocrim Rev. 19:798-827.III Vserossiiskaya naychno-prakticheskaya konferenciya "Aktyalnie problemi neiroendokrinologii" Moskva, 6-7 oktyabrya 2003 g.
2. Monson JP. The epidemiology of endocrine tumours. Endocrine-Related Cancer, 7,2000,29-36 selective pressure expressed at the uterine level. Am. J. Reprod. Immunol., 1999, V. 41, R 5-22.
3. Fournier A., Berrino R, Riboli E. et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer, 2005, V. 114, P. 448- 454.
4. Franke H. R., Kole S., Ciftci Z., Haanen C, Vermes I. In vitro effects of estradiol, 25 dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells. Cancer Lett, 2003, V. 190, P. 113-118.
5. Joachim R., Zenclussen A. C, Polgar B. et al. Steroids. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response, 2003, V. 68, P. 931-940.
6. Nielsen M., Thomsen J. L., Primdahl S. et al. Br. J. Cancer. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies, 1987, V. 56, P. 814-819.
7. Raghupathy R., Al Mutawa E., Makhseed M. et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG, 2005, V. 112, P. 1096-1101.
8. Szekeres-Bartho J., Polgar V., Kozma N. et al. Progesterone-dependent immunomodulation. Chem. Immunol. Allergy, 2005, V. 89, R 118-125.
9. Weiderpass E., Adami H. 0., Baron J. A. et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst, 1999, V. 91, P. 1131-1137.